The use of dendritic cells in cancer immunotherapy

被引：519

作者：

Schuler, G

Schuler-Thurner, B

Steinman, RM

机构：

[1] Univ Hosp Erlangen, Dept Dermatol, D-91052 Erlangen, Germany

[2] Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA

[3] Rockefeller Univ, Chris Browne Ctr Immunol & Immune Dis, New York, NY 10021 USA

来源：

CURRENT OPINION IN IMMUNOLOGY | 2003年 / 15卷 / 02期

关键词：

D O I：

10.1016/S0952-7915(03)00015-3

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A novel approach to vaccination against cancer is to exploit dendritic cells (DCs) as 'nature's adjuvants' and actively immunize cancer patients with a sample of their own DCs primed with tumor antigens. DC vaccination is, however, still at an early stage, slowed in part by the need to carry out research in humans. Nevertheless, valuable proofs of concept have been obtained with respect to the capacity of DCs to expand cancer-directed immune responses. The methods for preparing DCs are being improved continuously, and there are many opportunities to improve efficacy at the level of DC biology. An increased number of Phase I, II and III studies will drive this new area of human research.

引用

页码：138 / 147

页数：10

共 76 条

[1] Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination:: Cessation of CTL responses is associated with disease progression [J].